This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
As trial progresses new cases are still being reviewed by our lawyers investigating allegations of dangerous side effects from long-term Actos use by patients with Type 2 diabetes.
San Diego, CA (PRWEB) March 18, 2013
Resource4thePeople reported today that testimony is still being presented in a key trial involving allegations that long-term use of the diabetes treatment medication can cause bladder cancer.
In its most recent update for consumers about the first of numerous state court cases consolidated against Takeda Pharmaceutical Co. Resource4thePeople is providing new details about the progress of the trial in Superior Court of Los Angeles.*
The most recent news in the case involves the testimony of a witness who discussed the question of whether Takeda, Asia’s biggest drugmaker, put sales of its Actos diabetes drug ahead of concerns about consumer safety.**
“Because this case is the first to be tried of over 3,000 lawsuits that have been filed against Takeda Pharmaceuticals over allegations that long-term use of the medication puts diabetes patients at increased risk of bladder cancer it has generated substantial consumer interest,” said Resource4thePeople.
“Our legal experts say the results of this trial could have a substantial impact on the other cases in terms of whether there will be a greater chance of Takeda settling the other cases or also taking those to trial.
“Therefore, we will continue to provide trial information sought by our consumers seeking to keep abreast of the developments of the trial while continuing to provide free consultations by our lawyers for those who continue to contact us about their legal rights in regard to Actos use.”
Resource4thePeople said that Actos patients are continuing to inquire whether they are still eligible to file a lawsuit even though the first trial in the litigation is underway.
“The answer is yes, and those who wish to obtain a consultation with an experienced Actos bladder cancer lawyer for an evaluation of what compensation and legal options may be available to them should use the following link,” said Resource4thePeople.
In the Los Angeles trial, Bloomberg News reported that Howard Greenberg, a clinical pharmacologist, testified that Takeda officials, in 2005 e-mails, were concerned about whether U.S. and European drug regulators might force the company to issue warning labels about a bladder cancer risk and whether that might affect sales.**
“There are multiple e-mails from different levels of Takeda management that indicate the product came first,” Greenberg told jurors in the first day of testimony about Jack Cooper’s claims over Actos.
Cooper is suing Takeda over claims that he developed bladder cancer as a result of his use of Actos for more than four years, according to the court file in the case.
He is a retired telephone company worker who, according to the court file, was diagnosed with bladder cancer in 2011. His lawyer told jurors in opening statements that Cooper had been in “good shape” before he started on the medication, regularly walking five miles, repairing his own roof and going deep-sea fishing with his grandchildren, according to Bloomberg News.
The Los Angeles trial is one component of the Actos bladder cancer litigation. As this case proceeds other federal court cases that have been consolidated into a federal multi-district litigation are still pending.***
Multi-district litigations are designated by a special federal panel that chooses a single judge to oversee pre-trial evidence-gathering and other legal activities before deciding whether to grant such cases class-action status.
That judge, U.S. District Judge Rebecca Doherty, has scheduled the first bellwether trial in that litigation to be held in November. Bellwether trials are scheduled to allow attorneys for the plaintiffs and defendants to test the strength of their cases.
Concerns about Actos were raised by the U.S. Food and Drug Administration in 2011 after the agency staff reviewed a Takeda-sponsored study which documented an increased risk of developing bladder cancer with Actos than other diabetes drugs.****
Here is part of the safety announcement:
“The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines. The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer.”
“Consumers and diabetes patients should also be aware of the fact that in this health warning the FDA noted that Actos has been pulled from the pharmacy shelves in France and Germany but has not been recalled in the United States,” said Resource4thePeople.
Another important finding from medical research, according to Resource4thePeople, comes from the findings of a study recently published in Diabetic Medicine, which also links the use of Actos (pioglitazone) to increased risk of bladder cancer.*****
The findings were based on independent research and data from six other studies that included information taken from more than 215,000 diabetes patients.
The authors of the study reached the following conclusion, according to an abstract of the study:
“Pioglitazone use is associated with an increased risk of bladder cancer. Clinicians must consider this increased risk in the context of the baseline risk for bladder cancer of their patients, other adverse features of this medicine (e.g. weight gain, cost) and its potential anti-hyperglycaemic benefits.”
*Cooper v. Takeda Pharmaceuticals America, Inc., CGC-12-518535, California Superior Court (Los Angeles)
*** In Re: Actos (Pioglitazone) Products Liability Litigation, MDL2299 U.S. District Court, Western District of Louisiana
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/3/prweb10537426.htm